secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0000950170-24-027582
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint reports Q4/FY2023 results; positive Phase 2 data for EYP-1901 in wet AMD
--------------------------------------------------------------------------------

- Q4 net loss $14.1M ($0.33/sh) vs $43.5M ($1.16/sh) YoY; total net revenue $14.0M (+33%).
- Cash and investments $331M as of Dec 31, 2023, funding operations through Phase 3 topline data for wet AMD in 2026.
- Positive Phase 2 DAVIO 2 data: EYP-1901 met all primary/secondary endpoints; first Phase 3 trial expected 2H 2024.
- First patient dosed in Phase 2 VERONA trial for DME; topline data 1Q 2025; PAVIA NPDR data expected 2Q 2024.
- Appointed Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/0000950170-24-027582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/eypt-20240307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-027582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer